Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease 5.
Human peripheral blood mononuclear cells from healthy donors were treated ex vivo with the proteolytic enzyme bromelain and studied by flow cytometry. Bromelain-treated lymphocytes exhibited 60-90% reduced cell surface staining for CD44 and CD62-L molecules. While the staining for molecules CD16, CD56 and CD49d was unaffected, a moderate increase (10-40%) in expression of the beta(2)-integrins CD11a-c was seen. This selective modulation of cell adhesion molecules (CAM) was seen on T cells and NK cells, as well. The selective modulation of CAM may help explain some of the clinical effects observed after bromelain treatment in patients suffering from chronic inflammatory disease, HIV and cancer.
Kleef
R
R
Memorial Sloan-Kettering Cancer Center, New York, N.Y. 10021, USA.
Delohery
T M
TM
Bovbjerg
D H
DH
D000328:Adult; D001963:Bromelains / Q000494:pharmacology*; D018821:CD18 Antigens / Q000378:metabolism; D017252:CD3 Complex / Q000378:metabolism; D019002:CD56 Antigen / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000378:metabolism*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D066298:In Vitro Techniques; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects* / Q000378:metabolism*; D017452:Receptors, IgG / Q000378:metabolism
D018821:CD18 Antigens; D017252:CD3 Complex; D019002:CD56 Antigen; D015815:Cell Adhesion Molecules; D018960:Hyaluronan Receptors; D017452:Receptors, IgG; D001963:Bromelains